Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)
Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
1. In order to observe the benefit, side effects, and patient preference of Mirapex ER when
used in once-daily (QD) or twice-daily (BID) dosing
2. In order to estimate the conversion rate of dopamine agonists into Mirapex ER